Jennifer Maizel

Dr. Jennifer Maizel


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in Diabetes Spectrum
Verified
Journal Article
Closed access
PDF file
AWAshby F. Walker
Ashby F. Walker
AAAnanta Addala
Ananta Addala
ESEleni Sheehan
Eleni Sheehan
RLRayhan Lal
Rayhan Lal
MHMichael Haller
Michael Haller
DMDavid Maahs
David Maahs
Community health workers (CHWs) provide vital support to underserved communities in the promotion of health equity by addressing barriers related to the social determinants of health that often prevent people living with diabetes from achieving optimal health outcomes. Peer support programs in diabetes can also offer people living with diabetes invaluable support through a shared understanding of the disease and by offsetting diabetes-related stigma. As part of a Project Extension for Community Healthcare Outcomes (ECHO) Diabetes program, participating federally qualified healthcare centers were provided diabetes support coaches (DSCs) to facilitate patient engagement. DSCs hold invaluable expert knowledge, as they live with diabetes themselves and reside in areas they serve, thus combining the CHW role with peer support models. The use of DSCs and CHWs during the coronavirus disease 2019 pandemic and beyond is highly effective at reaching underserved communities with diabetes and promoting health equity.

15 June 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
JDJessica L. Dunne
Jessica L. Dunne
JMJennifer Maizel
Jennifer Maizel
APAmanda L. Posgai
Amanda L. Posgai
MAMark A. Atkinson
Mark A. Atkinson
LDLinda DiMeglio
Linda DiMeglio
OBJECTIVE: Women are broadly underrepresented in scientific leadership positions and their accomplishments are not provided equal recognition compared with those of men, but the imbalance in the field of diabetes is unknown. Hence, we analyzed multiple aspects of historical and present-day female representation in the diabetes field. RESEARCH DESIGN AND METHODS: We quantified gender representation at annual American Diabetes Association (ADA) meetings; editorial board service positions for ADA and the European Association for the Study of Diabetes (EASD) journals; principal investigators for ADA, JDRF, and National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases P30 grant funding; and ADA, JDRF, and EASD award recipients. RESULTS: There are many women in the field of diabetes: registration for the ADA Scientific Sessions has been 43% female since 2016, and for over five decades, women comprised 83% of ADA Presidents of Health Care and Education. Yet, only 9% of ADA Presidents of Medicine and Science have been women. Women were well represented on editorial boards for journals focused on diabetes education (Diabetes Spectrum, 89% female) and primary care (Clinical Diabetes, 49% female) but not for the more academically targeted Diabetes Care (34% female), Diabetes (21% female), and Diabetologia (30% female). Only one-third of ADA Pathway to Stop Diabetes and JDRF grants have been awarded to women, and females only lead 2 of 18 (11%) of the P30-supported Diabetes Research Centers. Finally, only 2–12% of major ADA, JDRF, and EASD awards were given to women, without significant change over time. CONCLUSIONS: Despite increasing recognition of gender imbalance in research and medicine, many disparities in the field of diabetes persist. We call for decreasing barriers for advancement of female investigators and creating environments that promote their retention and equitable recognition for their contributions to the field.

15 June 2021 in Diabetes
Verified
Journal Article
Closed access
PDF file
JDJessica L. Dunne
Jessica L. Dunne
JMJennifer Maizel
Jennifer Maizel
APAmanda L. Posgai
Amanda L. Posgai
MAMark A. Atkinson
Mark A. Atkinson
LDLinda DiMeglio
Linda DiMeglio
Women are broadly underrepresented in scientific leadership positions and their accomplishments are not provided equal recognition compared with those of men, but the imbalance in the field of diabetes is unknown. Hence, we analyzed multiple aspects of historical and present-day female representation in the diabetes field.We quantified gender representation at annual American Diabetes Association (ADA) meetings; editorial board service positions for ADA and the European Association for the Study of Diabetes (EASD) journals; principal investigators for ADA, JDRF, and National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases P30 grant funding; and ADA, JDRF, and EASD award recipients. There are many women in the field of diabetes: registration for the ADA Scientific Sessions has been 43% female since 2016, and for over five decades, women comprised 83% of ADA Presidents of Health Care and Education. Yet, only 9% of ADA Presidents of Medicine and Science have been women. Women were well represented on editorial boards for journals focused on diabetes education (Diabetes Spectrum, 89% female) and primary care (Clinical Diabetes, 49% female) but not for the more academically targeted Diabetes Care (34% female), Diabetes (21% female), and Diabetologia (30% female). Only one-third of ADA Pathway to Stop Diabetes and JDRF grants have been awarded to women, and females only lead 2 of 18 (11%) of the P30-supported Diabetes Research Centers. Finally, only 2–12% of major ADA, JDRF, and EASD awards were given to women, without significant change over time. Despite increasing recognition of gender imbalance in research and medicine, many disparities in the field of diabetes persist. We call for decreasing barriers for advancement of female investigators and creating environments that promote their retention and equitable recognition for their contributions to the field.

15 July 2022 in Journal of Ethnicity in Substance Abuse
Verified
Journal Article
Closed access
LKLindsey M. King
Lindsey M. King
TBTracey Barnett
Tracey Barnett
AAAcquel C. Allen
Acquel C. Allen
JMJennifer Maizel
Jennifer Maizel
RWRoneé E. Wilson
Roneé E. Wilson
We conducted a narrative literature review to examine contributing factors of disparities in tobacco usage and outcomes affecting Black Americans. We propose potential solutions that can be used to effectively address these disparities. We identified historical factors; socioeconomic factors; targeted marketing/advertising; the influence of racism/discrimination; neighborhood socioeconomic disadvantage; and mass incarceration. We call for more thorough examinations of these factors as a key element of tobacco-focused research and interventions to eliminate the disproportionate burdens faced by Black Americans. We advocate for greater emphases on the impacts of personal and structural racism on tobacco usage and outcomes affecting Black Americans.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
JMJennifer Maizel
Jennifer Maizel
MHMichael J. Haller
Michael J. Haller
DMDavid M. Maahs
David M. Maahs
AAAnanta Addala
Ananta Addala
SFStephanie L. Filipp
Stephanie L. Filipp
AWAshby F. Walker
Ashby F. Walker
Background: There are well‐documented disparities in diabetes care outcomes and technology usage, stemming from differences in healthcare access, distrust in healthcare providers, and other factors. This study evaluated patient‐level outcomes of a diabetes support coach (DSC) intervention aimed at improving underserved adults’ diabetes technology use, diabetes distress, and HbA1c levels. Methods: As part of a Project Extension for Community Healthcare Outcomes (ECHO) Diabetes program, a social support intervention involving 28 DSCs was piloted at 33 Federally Qualified Health Centers (FQHCs) in Florida and California from May 2021 to May 2022. DSCs, who were adults with diabetes, served in a capacity similar to peer mentors and community health workers and received uniform training/oversight by a clinical team. Intervention participants ( n = 74 adults with insulin‐requiring diabetes at FQHCs) self‐enrolled and engaged with DSCs via text messages, phone calls, and events. Participants’ outcomes were evaluated cross‐sectionally via the Diabetes Distress Scale (DDS‐17) and a diabetes technology usage survey and longitudinally via HbA1c tests upon enrollment and at 6‐month follow‐up. A group of adults with insulin‐requiring diabetes from the same FQHCs who did not receive the DSC intervention ( n = 363) was used for comparison. Descriptive statistics were computed for all outcomes ( n , percentage; mean, SD/95% CI). Between‐group comparisons were evaluated via chi‐squared and t ‐tests. Results: DSC intervention participants reported significantly lower diabetes distress than the comparison group (DDS‐17 score mean = 1.6 vs. 2.1, p < 0.001), and significantly more participants in the DSC intervention regularly used continuous glucose monitors (CGMs) than the comparison group (69.9% vs. 38.8%, p < 0.0001). There were no significant differences in insulin pump usage or HbA1c. Conclusions: Lower diabetes distress and greater CGM usage among intervention participants suggest that the DSCs’ shared lived experiences and healthcare navigation support positively influenced underserved adults’ outcomes. These findings show DSCs’ potential for improving diabetes care and technology equity.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
JMJennifer Maizel
Jennifer Maizel
AWAshby F. Walker
Ashby F. Walker
AWAnna Walls
Anna Walls
FPFrancisco J. Pasquel
Francisco J. Pasquel
MHMichael J. Haller
Michael J. Haller
BBBrittany S. Bruggeman
Brittany S. Bruggeman
Background: Patient utilization of diabetes technology differs based on sociodemographic and other factors. Underserved patients have reported that providers decline to prescribe continuous glucose monitors (CGMs) and insulin pumps. This qualitative study elucidated provider perspectives regarding facilitators and barriers to the prescription and patient use of diabetes technology. Methods: Sixteen diabetes care providers (75.0% MD, 18.8% APRN, 6.3% PharmD, and 50.0% adult endocrinology) at academic health centers, a Veterans Affairs Medical Center, and a safety net hospital in the southeastern United States were surveyed and interviewed from January to May 2024. Survey data were analyzed using descriptive statistics; a thematic analysis was used for interview transcripts with an adapted version of the social‐ecological model (SEM) as the coding framework. Results: On the survey, providers estimated that 80% (IQR 58.0%–86.0%) of their patients who met American Diabetes Association criteria for CGMs and 50% (IQR 48.0%–63.0%) for insulin pumps regularly used them. System factors (e.g., lack of insurance, high device costs, and insurance bureaucracy) were perceived by providers (62.5%–93.8%) as patients’ top barriers to use. Across the interviews ( n = 362 codes), providers’ top prescribing barriers were also system‐level (65.7%), including working with insurance, durable medical equipment (DME) companies, and pharmacies (15.7%), checking eligibility requirements (11.0%), and electronic health record (EHR) limitations (9.7%). Interpersonal prescribing barriers (7.5%) were tied to patients having low health literacy (3.6%) and communication with non–English‐speaking patients (1.7%). Individual prescribing barriers (26.0%) included patients expressing concerns about device adhesives/appearance (5.5%) and patients having limited knowledge/interest (3.0%). Facilitators across SEM levels included simplified eligibility criteria, EHR order sets, shared decision‐making, and proactive insurance/DME companies. Conclusions: These findings indicate the need for multilevel solutions to improve the prescription and use of diabetes technology. Future research and clinical practice should aim to enhance EHR functionality and system integration, improve patient‐provider communication, and streamline insurance criteria and processes.